701-301: A Phase 3 Switchover Study of the Efficacy and Safety of BMN 701 (Gilt-tagged Recombinant Human GAA) and Long-Term Study for Extended Treatment in rhGAA Exposed Subjects with Late-onset Pompe disease.

Project: Research project

Project Details

StatusFinished
Effective start/end date9/2/142/25/17

Funding

  • BioMarin Pharmaceutical Inc.